Myomo ® Application for Medicare Codes Receives Favorable Preliminary Decision

2018-05-14 08:00 ET - News Release
Company Website:
CAMBRIDGE, Mass. --  Myomo, Inc. (NYSE American:MYO) (“Myomo,” or the “Company”), a wearable medical robotics company, announces that the Centers for Medicare & Medicaid Services ("CMS") has published a favorable preliminary decision regarding the Company’s application for Healthcare Common Procedure Coding System (HCPCS) “L” codes. Myomo had filed its application in December 2017 to have CMS establish two new Level II HCPCS codes to describe “microprocessor-controlled, custom fabricated upper extremity braces.”
Read more: Myomo Inc ( MYO )

Tandem Diabetes Care Announces Preliminary First Quarter 2018 Results

SAN DIEGO -- Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today reported select, unaudited and preliminary results for the quarter ended March 31, 2018.
Pump shipments increased by 56 percent to approximately 4,400 pumps in the first quarter of 2018 from 2,816 pumps in the same period of 2017.
Sales increased by 42 percent to approximately $27.0 million in the first quarter of 2018 from $19.0 million in the same period of 2017. The first quarter of 2017 benefited from $1.5 million in previously deferred sales that were recognized during the period1.
Read more: Tandem Diabetes CareĀ® ( TNDM )

Entellus Medical Announces Definitive Agreement to be Acquired by Stryker Corporation for a Purchase Price of $24.00 Per Share in Cash

PLYMOUTH, Minn., Dec. 07, 2017  -- Entellus Medical, Inc. (NASDAQ:ENTL) announced today a definitive merger agreement by which Stryker Corporation (NYSE:SYK) will acquire Entellus in an all cash transaction for $24.00 per share, or an equity value of approximately $662 million.  The Entellus Board of Directors unanimously approved entering into the agreement.
“Entellus is a leader in the ENT segment and offers a comprehensive portfolio of products that enable physicians to conveniently and comfortably perform a broad range of ENT procedures,” stated Timothy J. Scannell, Group President, MedSurg and Neurotechnology at Stryker.
Read more: Entellus Medical Inc ( ENTL )

Second Sight Announces Market Entry into Iran with First Two Implants of Argus II Retinal Prosthesis System

- Marks Continued Global Expansion of Argus II for Individuals Blinded by Retinitis Pigmentosa -
SYLMAR, Calif. -- Second Sight Medical Products, Inc. (NASDAQ: EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision to blind patients, today announced market entry into Iran, implanting the first two patients with the Company’s Argus® II Retinal Prosthesis System (“Argus II”). The implant was facilitated by the country’s exclusive distribution partner, Arshia Gostar Darman Co. Ltd.
“These first implants in Iran are part of our strategy to selectively target and partner with leading eye centers and distribution partners around the world in order to increase the availability of the Argus II to individuals with Retinitis Pigmentosa. The adoption of Argus II by a growing number of centers globally is a testament to the increasing acceptance of our technology,” said Will McGuire, Chief Executive Officer of Second Sight.
Read more: Second Sight Medical Products ( EYES )

Exactech and TPG Capital Announce Amended Merger Agreement Providing for Increase in Merger Consideration to $49.25 per share

Merger with TPG Capital Now Valued at $737 Million
GAINESVILLE, Fla. -- Exactech, Inc. (Nasdaq: EXAC), a leading developer and producer of orthopaedic implant devices and surgical instrumentation for extremities and large joints, announced today that it has entered into an amendment to its merger agreement with TPG Capital and certain of its affiliates which was previously announced on October 23, 2017. Pursuant to the amended merger agreement, the Company’s common stock outstanding immediately prior to the effective time of the merger (other than certain shares held by the Company’s founders and certain management shareholders) will be converted into the right to receive $49.25 per share in cash. This represents an increase of approximately 17.3% over the $42.00 of per share merger consideration previously agreed to by Exactech and TPG Capital. TPG Capital has also increased its equity financing commitment to $737 million for purposes of consummating the merger.
Read more: Exactech Inc ( EXAC )

Videos / Webinars

View all videos